Is the GSK Settlement Sufficient


An article in the New England Journal of Medicine asks whether settlements such as the $3 billion GlaxoSmithKline agreed to last July regarding off-label marketing of Paxil and Wellbutrin are sufficient to change corporate behavior, and proposes possible improvements to the system.

Article → 

Outterson, J. “Punishing Health Care Fraud – Is the GSK Settlement Sufficient?


Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.

Previous articleBarMittzva Romba: Dance of the Sugar Plum Fairies
Next articleIcarus Project Ten Years Later
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]